| Spirulina — the common commercial name for edible dried biomass of filamentous cyanobacteria historically classified as Spirulina, particularly Arthrospira platensis and related species, with modern taxonomy frequently using Limnospira platensis. It is classified as a cyanobacterial whole-food/nutraceutical rather than a single chemical compound. Common abbreviations include SP for spirulina and AP for Arthrospira platensis. Major bioactive constituents include C-phycocyanin, phycocyanobilin, carotenoids, phenolic compounds, sulfated and other polysaccharides, peptides, γ-linolenic acid, chlorophyll derivatives, vitamins, minerals, and a high protein fraction. C-phycocyanin is one of the best-characterized anticancer constituents, but purified phycocyanin should be considered pharmacologically distinct from whole Spirulina biomass.
- C-phycocyanin (C-PC) is commonly around 10–20% of dry weight
- Allophycocyanin (APC) ~2–5%
- APC:C-PC ratio roughly 1:4 to 1:10
- currently insufficient evidence that APC enhances the oral bioavailability of C-PC.
Primary mechanisms (ranked):
- Induction of tumor-cell apoptosis through mitochondrial and death-receptor pathways, including ↑ Bax and caspase signaling and ↓ Bcl-2 survival signaling.
- Suppression of proliferative signaling and cell-cycle progression, including modulation of PI3K/Akt, MAPK and related growth pathways with G1/S or G2/M arrest depending on cancer model.
- Immune modulation, including enhancement of NK-cell and T-cell activity, macrophage polarization and modulation of inflammatory cytokine signaling.
- Suppression of angiogenesis and tumor progression, including ↓ VEGF/VEGFR2 signaling, migration, invasion and epithelial-mesenchymal transition.
- Redox modulation: Spirulina is generally antioxidant in normal tissues, whereas C-phycocyanin and other components can produce context-dependent oxidative stress or ROS-dependent apoptosis in some cancer cells.
- Suppression of pro-inflammatory signaling, particularly NF-κB-associated inflammatory pathways.
- Chemosensitization and treatment-support effects reported preclinically, with limited human evidence suggesting reduced chemotherapy-associated myelosuppression rather than established enhancement of tumor response.
Bioavailability / PK relevance: Whole Spirulina is orally consumed, but systemic delivery of intact macromolecular constituents is limited. C-phycocyanin is a large protein susceptible to gastrointestinal degradation, while its chromophore phycocyanobilin and smaller digestion products may contribute to systemic activity. Animal pharmacokinetic data indicate very low circulating phycocyanobilin concentrations after oral C-phycocyanin exposure. Composition and release of bioactives vary substantially with strain, cultivation, processing, extraction and product formulation.
In-vitro vs systemic exposure relevance: Many anticancer experiments use purified C-phycocyanin, concentrated extracts or individual Spirulina metabolites at concentrations substantially above systemic levels expected after ordinary oral intake of whole Spirulina. These experiments therefore support mechanistic plausibility but should not be interpreted as direct evidence that gram-level dietary Spirulina reproduces the same tumor exposures. Gastrointestinal and immunological effects may remain relevant without high systemic concentrations.
Clinical evidence status: Predominantly preclinical for direct anticancer treatment. A small randomized human study reported regression of oral leukoplakia with 1 g/day Spirulina fusiformis, although recurrence after discontinuation was common. A randomized study in chemotherapy-treated cancer patients reported improved leukocyte/neutrophil preservation and reduced severe myelosuppression, supporting possible adjunctive supportive use rather than proven anticancer efficacy. Spirulina is not an established or approved cancer therapy.
Spirulina Cancer Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Intrinsic and Extrinsic Apoptosis |
↑ Bax, ↑ caspases, ↓ Bcl-2, ↑ apoptosis |
↔ or cytoprotective (context-dependent) |
G |
Apoptotic tumor-cell death |
One of the most consistently reported anticancer effects, particularly for C-phycocyanin and Spirulina-derived bioactive fractions. |
| 2 |
PI3K Akt Survival Signaling |
↓ Akt signaling, ↑ PTEN in some models |
↔ (context-dependent) |
R/G |
Reduced survival and proliferation |
Observed with C-phycocyanin in multiple tumor models; exact upstream targets vary considerably by preparation and cell type. |
| 3 |
Cell Cycle Control |
↓ proliferation, ↑ G1/S or G2/M arrest |
↔ (model-dependent) |
G |
Growth arrest |
Cell-cycle phase affected depends on cancer type and Spirulina-derived preparation. |
| 4 |
Antitumor Immune Modulation |
↑ immune-mediated tumor surveillance |
↑ NK activity, ↑ cellular immune responses (context-dependent) |
G |
Enhanced antitumor immunity |
Polysaccharides and phycocyanin contribute to immunomodulation; evidence is stronger for biological response modulation than direct clinical tumor control. |
| 5 |
VEGF Angiogenesis |
↓ VEGF/VEGFR2 signaling |
↔ (model-dependent) |
G |
Reduced angiogenesis |
Predominantly preclinical evidence. |
| 6 |
Migration EMT and Metastatic Signaling |
↓ EMT, ↓ migration, ↓ invasion |
↔ |
G |
Reduced metastatic phenotype |
Reported mainly for phycocyanin and defined extracts rather than standardized whole Spirulina. |
| 7 |
NF-κB Inflammatory Signaling |
↓ NF-κB-associated signaling (context-dependent) |
↓ excessive inflammatory signaling |
R/G |
Anti-inflammatory and antiproliferative effects |
May contribute both to tumor-pathway modulation and protection of normal tissue from inflammatory injury. |
| 8 |
ROS Redox Modulation |
↑ ROS in some tumor models; ↓ oxidative stress in others (context-dependent) |
↓ ROS and oxidative damage |
P/R |
Selective redox modulation |
Do not classify Spirulina simply as a pro-oxidant. Whole Spirulina is strongly associated with antioxidant activity, while purified components can trigger ROS-dependent cancer-cell apoptosis. |
| 9 |
NRF2 Antioxidant Response |
↔ or context-dependent |
↑ NRF2-associated cytoprotection (context-dependent) |
R/G |
Secondary antioxidant response |
More relevant to normal-tissue protection and antioxidant effects than as a primary anticancer mechanism. |
| 10 |
Chemosensitization and Chemoprotection |
↑ drug response reported in selected preclinical models |
↓ treatment-associated oxidative injury and myelosuppression (context-dependent) |
G |
Potential adjunctive effect |
Human evidence is more persuasive for supportive effects during chemotherapy than for increased tumor killing. |
| 11 |
Clinical Translation Constraint |
↓ achievable systemic exposure |
↔ |
G |
Limits extrapolation from laboratory studies |
Whole-biomass composition is variable; C-phycocyanin is gastrointestinally unstable and has limited systemic bioavailability. Many in-vitro studies use purified constituents or concentrations not reproduced by oral Spirulina supplementation. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
|